Blog
CANTAB assessments used in EBBINGHAUS cognitive function trial for Amgen's evolocumab
Cambridge Cognition today reports its involvement in Amgen's EBBINGHAUS study with full results being presented at the American College of Cardiology Annual Scientific Session on 18 March 2017.
Design and rationale of the EBBINGHAUS trial
The Journal Clinical Cardiology has published on the design and rationale of the EBBINGHAUS trial: A phase 3, double-blind, placebo controlled, multicenter study to assess the effect of the human anti-PCSK9 monoclonal antibody evolocumab on cognitive function in patients with clinically evident cardiovascular disease receiving statin background lipid-lowering therapy1.
web-based testing,
wearables,
virtual clinical trials,
technology,
swm,
stigma,
social cognition,
smartphones,
schizophrenia research,
schizophrenia,
safety,
rvp,
rti,
research funding,
research,
remote testing,
regulations,
recruitment,
rare disease,
prodromal,
pro-cognitive,
prm,
press release,
presenteeism,
precision psychiatry,
pre-clinical,
poster,
personalised medicine,
patient recruitment,
patient engagement,
parkinson's disease,
pal,
paired associates learning,
ots,
occupational health,
normative data,
neurotech,
neuroscience,
neurology,
near-patient testing,
multiple sclerosis,
mts,
ms,
modelling,
mental wellbeing,
mdd,
mci,
major depression,
high frequency,
healthcare,
guide,
grant,
funding,
fatigue,
ert,
epidemiology,
ebt,
ebbinghaus,
early career researchers,
early alzheimer's disease,
drug development,
dms,
digital tools,
digital health,
depression,
dementia,
covid-19,
cognitive testing,
cognitive science,
cognitive safety,
cognitive load,
cognitive impairment,
cognitive function,
cognitive dysfunction,
cognitive biomarkers,
cognitive assessment,
cognition kit,
cognition,
cns summit,
clinical trials,
cias,
chronic illness,
chronic health conditions,
cgt,
cantab testimonial,
cantab research grant,
cantab,
cambridge cognition,
brain health,
biomarkers,
awards,
automatic speech recognition,
autism,
attention,
asr,
asd,
alzheimer's disease,
adolescents,
academic,
absenteeism,
